ConjuChem Biotechnologies, Inc. (TSX: CJB) announced today that it has established a special committee of independe...
[ ... to read the whole article, subscription is required ... ]
... ... nsaction or other strategic alternative but there is an expectation that this process will result in a transaction or...
To read this or any other article, or trial test our database, please try
our 7 days or 1 month subscription,
Click Here for Details.
Company Deals and People
|
Date |
Title |
Type |
2009/5/15 |
Chantal Lapointe, VP, Finance |
Management |
2008/5/28 |
William K. Heiden |
Director |
2007/12/13 |
ConjuChem Biotechnologies Closes Debenture Offering |
Financing |
2007/9/4 |
Jean Silveri, VP, General Counsel |
Management |
2006/11/28 |
ConjuChem Biotechnologies Completes Major Financing |
Financing |
2006/5/18 |
ConjuChem Completes Prospectus Offering |
Financing |
2006/5/11 |
Thomas R. Ulich, EVP, Research and Development |
Management |
2005/10/13 |
Mark D. Perrin, President & CEO |
Management |
2005/2/14 |
ConjuChem Completes $21.7 Million Bought Deal Financing |
Financing |
2004/8/20 |
ConjuChem Completes $15 Million Convertible Debt Financing |
Financing |
2003/10/6 |
ConjuChem Completes $21.7 Million Bought Deal |
Financing |
2003/6/27 |
ConjuChem Closes $12 Million Bought Deal Financing |
Financing |
2002/11/20 |
Jacques Lapointe, Chairman |
Director |
2001/12/6 |
ConjuChem Closes $30 Million Convertible Debt Financing |
Financing |
2001/6/29 |
ConjuChem Closes $38.1 Million Offering - $19.4 Million by Selling Shareholders |
Financing |
2001/2/15 |
Lennie Ryer, VP & CFO |
Management |
